We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immunocore Holdings plc (IMCR) ADS EACH REPR ONE ORD SHS

Sell:$28.50 Buy:$28.56 Change: $1.28 (4.26%)
NASDAQ:0.23%
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$28.50
Buy:$28.56
Change: $1.28 (4.26%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$28.50
Buy:$28.56
Change: $1.28 (4.26%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Contact details

Address:
90 Park Drive, Milton Park, Abingdon
ABINGDON
OX14 4RY
United Kingdom
Telephone:
+44 (1235) 438600
Website:
www.immunocore.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMCR
ISIN:
US45258D1054
Market cap:
$1.52 billion
Shares in issue:
50.03 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Bahija Jallal
    Chief Executive Officer, Executive Director
  • Travis Coy
    Chief Financial Officer, Executive Vice President, Head of Corporate Development
  • Tina St Leger
    Chief Human Resource Officer
  • David Berman
    Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.